ESMA deprioritises or postpones set of 2025 Commission deliverables

ESMA publishes letter to the Commission outlining several of its 2025 deliverables which could be deprioritised or postponed.

11 March 2025

Publication

Loading...

Listen to our publication

0:00 / 0:00

What's new?

On 6 March 2025, the European Securities and Markets Authority (ESMA) published a letter (dated 03 March 2025) from its Chair, Verena Ross, to the European Commission  outlining a number of Commission deliverables for 2025 which could be deprioritised or postponed to re-allocate resources to its highest priority workstreams.

This followed ESMA's assessment of the commitments outlined in its 2025 Annual Work Programme (AWP) as part of a wider effort to increase efficiency and in light of external factors impacting ESMA's workload since the publication of the 2025 AWP.

Among the deprioritised or postponed deliverables are:

  • AIFMD Review: RTS on open ended loan originating alternative investment funds (initial deadline of 16 April 2025 delayed by 6 months)

  • MiFIR/D Review:

    • Guidelines on communication methods to SME Growth Markets issuers when trading an instrument on another trading venue (Cancelled)

    • RTS on CTP incidents statistics reporting (initial deadline of 1 September 2025 delayed by 3 months)

    • RTS on order execution policies (initial deadline of 29 December 2024 delayed by 6 months)

  • UCITS Eligible Assets Directive: technical advice on eligible assets (initial deadline of April 2025 delayed by 3 months)

Other topics included in the annex to ESMA's letter and subject to delay or cancellation include:

  • CSDR Refit
  • EMIR 2
  • EMIR 3
  • Listing Act
  • CCP RRR
  • DLT Pilot
  • Recurrent mandatory reports

This document (and any information accessed through links in this document) is provided for information purposes only and does not constitute legal advice. Professional legal advice should be obtained before taking or refraining from any action as a result of the contents of this document.